Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug's impact on fibrosis and weight ...

Biocryst is offloading part of its business for $250 million. Meanwhile, the former FDA leader took issue with a new policy ...

Despite calls for the meeting to be delayed, Wednesday’s meeting of the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) went ahead.

Health news includes a cyberattack affecting patient care in London, Walgreens' financial success amid strategic changes, ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

US biopharma company Altimmune saw its share slump almost 55% to $3.48 yesterday, after it announced what it called ‘positive ...

Detailed price information for Citigroup Cap XiII [C/Pn] (C-N-N) from The Globe and Mail including charting and trades.